News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
701,141 Results
Type
Article (41612)
Company Profile (464)
Press Release (659065)
Section
Business (208401)
Career Advice (2009)
Deals (35943)
Drug Delivery (92)
Drug Development (83304)
Employer Resources (169)
FDA (16326)
Job Trends (15048)
News (352100)
Policy (32980)
Tag
Academia (2619)
Alliances (50609)
Alzheimer's disease (1273)
Approvals (16251)
Artificial intelligence (139)
Bankruptcy (361)
Best Places to Work (11735)
Biotechnology (349)
Breast cancer (124)
Cancer (1115)
Cardiovascular disease (102)
Career advice (1677)
Cell therapy (248)
Clinical research (66001)
Collaboration (408)
Compensation (199)
COVID-19 (2590)
C-suite (100)
Data (1138)
Diabetes (156)
Diagnostics (6197)
Earnings (86044)
Employer resources (147)
Events (112928)
Executive appointments (316)
FDA (16871)
Funding (366)
Gene therapy (193)
GLP-1 (611)
Government (4409)
Healthcare (18996)
Infectious disease (2675)
Inflammatory bowel disease (113)
Interviews (309)
IPO (16575)
Job creations (3695)
Job search strategy (1433)
Layoffs (439)
Legal (7929)
Lung cancer (174)
Manufacturing (181)
Medical device (13322)
Medtech (13327)
Mergers & acquisitions (19432)
Metabolic disorders (426)
Neuroscience (1564)
NextGen Class of 2024 (6734)
Non-profit (4533)
Northern California (1496)
Obesity (245)
Opinion (199)
Patents (103)
People (57631)
Phase I (20683)
Phase II (29138)
Phase III (21546)
Pipeline (459)
Postmarket research (2590)
Preclinical (8881)
Radiopharmaceuticals (252)
Rare diseases (234)
Real estate (5999)
Regulatory (21956)
Research institute (2403)
Resumes & cover letters (352)
Southern California (1324)
Startups (3747)
United States (13873)
Vaccines (565)
Weight loss (183)
Date
Today (136)
Last 7 days (820)
Last 30 days (3906)
Last 365 days (36719)
2024 (33681)
2023 (41014)
2022 (52276)
2021 (56766)
2020 (54926)
2019 (47420)
2018 (35699)
2017 (33026)
2016 (32348)
2015 (38398)
2014 (32189)
2013 (27111)
2012 (29220)
2011 (29863)
2010 (27995)
Location
Africa (732)
Arizona (200)
Asia (38515)
Australia (6403)
California (3418)
Canada (1293)
China (252)
Colorado (148)
Connecticut (162)
Europe (83999)
Florida (462)
Georgia (116)
Illinois (354)
Indiana (199)
Kansas (99)
Maryland (590)
Massachusetts (2727)
Michigan (159)
Minnesota (278)
New Jersey (970)
New York (973)
North Carolina (758)
Northern California (1496)
Ohio (141)
Pennsylvania (852)
South America (1106)
Southern California (1324)
Texas (476)
Utah (92)
Washington State (374)
701,141 Results for "dice therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Lilly Completes Acquisition of DICE Therapeutics
Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE).
August 9, 2023
·
4 min read
Deals
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
Eli Lilly and Company and DICE Therapeutics, Inc. announced a definitive agreement for Lilly to acquire DICE.
June 20, 2023
·
9 min read
Biotech Bay
DICE Therapeutics to Participate in the Bank of America Securities 2023 Healthcare Conference
DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company) today announced management will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023 at 3:00 p.m. PT / 6:00 p.m. ET.
May 3, 2023
·
1 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Biotech Bay
DICE Therapeutics to Host R&D Investor Event on Tuesday, June 20, 2023
DICE Therapeutics, Inc. announced that management will host a research & development day on Tuesday, June 20, 2023 from 12:00 p.m. – 2:30 p.m. ET in New York, NY.
June 13, 2023
·
1 min read
Biotech Bay
DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company) today announced management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 4:00 p.m. ET.
March 23, 2023
·
1 min read
Business
DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company) today reported financial results for the fourth quarter and full year ended December 31, 2022 and highlighted recent corporate achievements.
March 15, 2023
·
8 min read
Deals
Lilly Announces Extension of Tender Offer to Acquire DICE
Eli Lilly and Company announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares of common stock of DICE Therapeutics, Inc., for a purchase price of $48 per share in cash, without interest and less any applicable tax withholding.
July 25, 2023
·
7 min read
Business
DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, reported financial results for the first quarter ended March 31, 2023, and highlighted recent corporate achievements.
May 11, 2023
·
8 min read
Biotech Bay
DICE Therapeutics to Participate at Upcoming Investor Conferences - February 08, 2023
DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, announced management will participate at the following investor conferences.
February 8, 2023
·
1 min read
1 of 70,115
Next
